Recent literature has focused on the role of the gut and increased gut permeability as a driver of systemic inflammation in critical illness. Thus, the therapeutic potential for an agent to prevent gut barrier compromise and attenuate gut-derived inflammatory response is significant.
Introduction
The role of the gut in critical illness has been the focus of a great deal of debate and research. The potential for the gut to be both a target and causative agent of injury in critical illness is an area of avid study currently. Clearly, the gut becomes a target organ for injury following critical illness. This is typically manifested by an alteration of gut epithelial cell function [1] . Specifically, data reveals that gut epithelial permeability increases following stresses such as hypoxia, oxidant stress, nitric oxide exposure and exposure to cytokines [1] . This effect was long thought to lead to an increase in bacterial translocation to the blood leading to bacteremia. This phenomenon is often blamed for systemic bacteremias of unknown origin, particularly Gram-negative bacteremias. This subject has been a controversial topic of debate in recent years, as the limited human data available seems to contradict popular opinion and indicate that gut-derived bacterial translocation into the systemic circulation (portal vein) does not occur. This data is derived primarily from Moore et al.'s work in trauma patients showing virtually no confirmable episodes of positive portal vein bacterial cultures in patients following severe trauma and emergency laparotomy [2] . An attractive alternative hypothesis has, however, been put forward by Deitch et al. [3] describing the gut as a cytokine-generating organ and that these inflammatory products reach the systemic circulation not via the portal vein, but via the mesenteric lymph and, subsequently, the thoracic duct. This data is supported by a study of intensive care unit patients in which thoracic duct lymph was not found to contain bacteria or increased levels of endotoxin in patients who developed multiple organ dysfunction syndrome (MODS); however, MODS patients had higher levels of lymph cytokines and cytokine receptor antagonists [4] . The essential premise of this concept is that bacteria are translocating across the intestinal mucosal barrier locally and causing activation of the gut inflammatory response leading to the elaboration of proinflammatory cytokines, which then lead to downstream organ injury. This may be a potential cause of the acute respiratory distress syndrome following critical illness or injury as the lung is among the first organs to encounter the potentially toxic drainage of the thoracic duct. Thus, it appears that the gut may function as a causative agent of the progression of critical illness by driving the systemic inflammatory response which ultimately leads to MODS and death.
Based on this premise of the gut as both a target and causative agent of injury in critical illness, an ideal therapy to prevent the injury and subsequent driving of systemic inflammatory response syndrome would be one that (1) would protect the gut epithelial cell against injury and (2) attenuate the elaboration of proinflammatory mediators by gut-based immune cells. One agent shown to accomplish these goals is the conditionally essential amino acid glutamine (GLN). This review will cover the literature examining the use of glutamine to achieve these mechanistic goals and the limited clinical literature that has looked at the efficacy of GLN in affecting the gut in critical illness.
Laboratory data
A great deal of recent literature has examined the mechanisms by which GLN may benefit the gut in critical illness. These potential mechanistic pathways are summarized in Table 1 and Fig. 1 .
Gut cell/tissue protection
Data from our laboratory and others indicate that one of the most important mechanism by which GLN functions to protect the gut against injury and increases in permeability is via enhanced expression of heat shock proteins (HSPs). HSPs are highly conserved proteins present in all cells, and fundamental to the cellular and tissue response to stress and injury [5] . Expression of these proteins can protect cellular proteins from damage and prevent cellular injury and death [5, 6] . We have shown that GLN enhances HSP-70 in intestinal epithelial cells and this enhancement correlates with improved cell survival following oxidant stress. Further, when HSP expression is inhibited by quercetin [an inhibitor of heat shock factor (HSF)-1 activation -a transcription factor for HSP expression] or antisense inhibition of the gene for HSP-70, GLN's protective effects are abrogated [7, 8] . Additional research in animal models of shock and sepsis have revealed that GLN can enhance tissue (including intestinal tissues) HSP-70 and HSP-25/27 levels [9,10 ]. These increased levels correlate with enhanced survival from these animal models of critical illness. In a model of gut-derived endotoxemia (lethal heat stroke) we showed that oral GLN administration could attenuate increases in gut permeability and plasma endotoxemia [11 ] . This was correlated with increased gut HSP-70 expression and improved survival. Additional evidence for the HSP-expression paradigm was recently published in revealing that heme-oxygenase-1 (HSP-32) may also be critical to GLN's protection of the intestine against injury [12 ] . Given this data, our laboratory hypothesized that GLN may act as a HSF-1 activator and increase the entire family of HSPs following stress or injury. We have recently published data that indicate that in HSF-1 knockout cells GLN's ability to generate an HSP response is lost and the protection conferred by GLN is also completely abrogated [13 ]. Utilizing HSP-70 knockout mice we have also shown that HSP-70 expression is vital for rodent survival following sepsis [14 ] . Utilizing these same mice we have found that GLN protects HSP-70 wild-type mice following sepsis, but is unable to protect mice with a gene deletion of HSP-70 from experimental sepsis (unpublished data).
Perhaps equally relevant is that GLN administration can prevent the occurrence of acute respiratory distress syndrome following polymicrobial sepsis [10 ], and histologically defined lung and gut injury following endotoxin-derived shock [9]. This lung protection is lost in mice with a specific deletion of the HSP-70 gene (unpublished data). This lends support to the potential for GLN pharmacotherapy to prevent potentially gut-derived MODS following sepsis or shock.
We recently completed a pilot trial examining the potential for GLN to enhance HSP-70 expression in critically ill patients. This double-blind trial examined patients in the surgical intensive care unit who required total parenteral nutrition for greater then 5 days and were randomized to receive GLN (given as alanyl-GLN, 0.5 g/kg/day) or an iso-nitrogenous control. This subtrial specifically examined the expression of HSP-70 at 7 days following initiation of GLN or isonitrogenous control and correlated this level with outcome. GLN treatment enhanced serum HSP-70 expression (3.7-fold increase versus iso-nitrogenous control, 95% confidence interval 1.5-11.9, P ¼ 0.029) and this enhanced HSP-70 expression correlated with a decrease in intensive care unit length of stay (P < 0.009 versus control) [15 ] . This study demonstrated that GLN was the first nontoxic, clinically relevant enhancer of HSP-70 expression in critically ill patients. 
Prevention of apoptosis
A number of recent in-vitro studies [16 ,17 ] have examined the role of GLN in preventing apoptosis following stress or injury. One study of note by Evans et al. indicated that GLN can prevent intestinal cell apoptosis via the pyrimidine pathway [16 ] . This provides an interesting mechanistic explanation for GLN's benefits. Another interesting study demonstrated that oral GLN could prevent increases in gut apoptosis and gut permeability in rats with obstructive jaundice [18 ] . Many of these studies were reviewed in a recently published article [19 ] .
Antiinflammatory
Previous literature has examined the role of GLN in regulating the immune response [20] [21] [22] . Focus of recent studies has been on GLN's ability to attenuate the inflammatory response via effects on the NF-kB and IkBa signaling pathways. Our laboratory recently completed a trial in the cecal ligation and puncture model of sepsis in the rat showing a single dose of GLN (0.75 g/kg) can attenuate nuclear binding/activation of NF-kB and prevent the degradation of its inhibitory protein IkBa [23 ] . This study also revealed that GLN could inhibit the activation of the stress kinase pathway including p38 mitogen-activated protein kinase and extracellular signal-regulated kinase. This effect led to attenuated tumor necrosis factor-a, and interleukin(IL)-6 and -18 expression following sepsis. These findings have been supported by data showing GLN can attenuate IL-6 release in septic mice following cecal ligation and puncture [24 ] .
Specific to the gut, Kozar et al. have performed a number of elegant studies examining the role of GLN and other nutrients on gut ischemia/reperfusion (I/R) injury. Their data reveal that following gut (I/R) injury GLN can activate peroxisome proliferator-activated receptor-DNA binding. peroxisome proliferator-activated receptor-g is a vital transcription factor known to attenuate the inflammatory response by interference with proinflammatory pathways (such as NF-kB and AP-1). This activation was correlated with attenuation of injury via gut histology and myeloperoxidase activity (which reflects inflammation in the gut) [25 ] . Kozar also showed that GLN, but not alanine, maintains small bowel barrier function following gut I/R injury in rats [26] .
Preservation of tissue metabolic function
A recent hypothesis indicates that multisystem organ failure following shock and sepsis may be due to tissue metabolic dysfunction [27] . We have shown that GLN can preserve tissue level metabolic function in the face of sepsis, shock and I/R injury [10 , 28 ,29] . This effect appears to be tied to enhanced HSP expression [10 ,28 ].
Antioxidant/attenuation of inducible nitric oxide synthase expression
GLN has long been known to be an important precursor of glutathione, a vital antioxidant molecule, during I/R injury [29, 30] . Recent data reveals that GLN can attenuate inducible nitric oxide synthase expression following I/R injury and sepsis [23 ,31] . Specific to the gut, a recent study demonstrated oral GLN could attenuate oxidative stress and mitochondrial injury in the gut following operative manipulation of the intestines. Supporting the hypothesis of the gut as a 'motor' that drives systemic inflammation, GLN also attenuated oxidative injury in the lung in this study [32 ] .
Clinical data on glutamine and gut protection in critical illness
A recent meta-analysis examined the question of GLN's effect on gut permeability [33 ] . The authors of this review begin by concluding that in the studies with better design and more appropriate controls there is a signal indicating that intestinal permeability is increased in critically ill patients. They rightly indicate that these results have not always been consistent, but that the negative results have occurred in less well-designed studies. Traditionally (and in the studies reviewed by the authors), intestinal permeability measures have been performed by measuring the urinary excretion of two probes. Typically, these have been nonmetabolizable saccharides such as lactulose and mannitol [1]. This method of intestinal permeability has recently been questioned [1] . Concerns have included that the markers utilized for measurement of gut permeability may not be reliable indicators. The limitation of these markers was recently reviewed by Fink [1] . As a result, the real clinical significance of findings generated utilizing these methods may be left to question until more research on their accuracy is completed, although, as these measurement methods do have inherit limitations, it is likely that intestinal barrier dysfunction is a component of critical illness and, more importantly, MODS that often accompanies critical illness [1].
The authors of the review then address the role GLN may play in attenuating increases in intestinal permeability. The authors indicate that in a small number of studies of burn patients and patients undergoing major abdominal surgery, GLN administration leads to an improvement in gut permeability as measured via lactose/mannitol ratios [33 ] . It is difficult to make any inferences from this limited data.
One study has been published that was not included in the aforementioned meta-analysis article. A small study by Quan et al. [34] examined 20 patients undergoing abdominal surgery. Ten patients received GLN 30 g/day for 7 days and the other group received a placebo. This study indicated that following surgery GLN attenuated the rise in lactose/mannitol ratio observed in the control group and reduced serum markers of oxidant stress.
Conclusion
Currently there is a great deal of mechanistic data supporting the use of GLN as a vital intervention to attenuate gut injury and gut-derived systemic inflammation in critical illness. The clinical data for GLN as a 'gut'supportive nutrient in critical illness is much more limited. Existing data demands that the appropriate multicenter and mechanistic clinical trials be carried out to answer this question.
Examining clinical trial data indicates an increasing number of studies showing GLN can reduce mortality and improve outcome in critically ill patients. This data was reviewed in a recent meta-analysis by Novak et al. [35] . An update of this data with more recently published studies indicates that GLN does have a statistically significant effect on reducing mortality and infection in critical illness. This data is available online at www. criticalcarenutrition.com. An interesting finding of a number of these studies is that GLN administration to severe burn patients and trauma patients nearly eliminates the occurrence of Gram-negative (or, some have implied, 'gut-derived') bacteremia and sepsis [36] [37] [38] . This makes mechanistic sense, given GLN's protective effect on the gut; however, when taken with a lack of human evidence for bacterial translocation to the systemic circulation the cause of GLN's protective effect against Gram-negative bacteremia is still unclear. Currently, additional studies are needed to clarify GLN's most important protective mechanism in protection against increases in intestinal permeability and gutderived inflammation. Further, large-scale studies of GLN's effect on clinical outcomes are indicated. These studies, as all studies of future interventions utilizing nutritional pharmacology, should be performed with GLN alone and not in combination with other pharmacologic nutrients (i.e. arginine). Additionally, it would be useful to examine the effect of GLN on gutderived inflammation and MODS, particularly focusing on the appearance of inflammatory mediators in the lymph.
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